Assenagon Asset Management S.A. Acquires 111,686 Shares of STAAR Surgical Company $STAA

Key Points

• Assenagon Asset Management S.A. has increased its holdings in STAAR Surgical Company by 213.1%, acquiring an additional 111,686 shares for a total of approximately 164,088 shares.
• Other institutional investors, including Armistice Capital LLC and Broadwood Capital Inc., have also significantly raised their stakes in STAAR Surgical during the first quarter.
• Multiple research analysts have recently upped their price targets for STAAR Surgical, with Canaccord Genuity Group increasing its target from $20.00 to $28.00 and maintaining a "hold" rating.

Assenagon Asset Management S.A. raised its holdings in STAAR Surgical Company (NASDAQ:STAA - Free Report) by 213.1% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 164,088 shares of the medical instruments supplier's stock after acquiring an additional 111,686 shares during the period. Assenagon Asset Management S.A. owned approximately 0.33% of STAAR Surgical worth $2,753,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Armistice Capital LLC increased its position in shares of STAAR Surgical by 244.0% in the first quarter. Armistice Capital LLC now owns 3,000,000 shares of the medical instruments supplier's stock worth $52,890,000 after purchasing an additional 2,128,000 shares during the last quarter. Broadwood Capital Inc. grew its stake in STAAR Surgical by 14.8% in the 1st quarter. Broadwood Capital Inc. now owns 12,455,264 shares of the medical instruments supplier's stock worth $219,586,000 after buying an additional 1,606,633 shares in the last quarter. Yunqi Capital Ltd increased its holdings in shares of STAAR Surgical by 152.5% in the 1st quarter. Yunqi Capital Ltd now owns 1,937,589 shares of the medical instruments supplier's stock worth $34,160,000 after buying an additional 1,170,176 shares during the last quarter. Resona Asset Management Co. Ltd. increased its holdings in shares of STAAR Surgical by 44.6% in the 1st quarter. Resona Asset Management Co. Ltd. now owns 2,169,618 shares of the medical instruments supplier's stock worth $38,358,000 after buying an additional 669,430 shares during the last quarter. Finally, Jupiter Asset Management Ltd. raised its position in shares of STAAR Surgical by 50.1% during the 1st quarter. Jupiter Asset Management Ltd. now owns 566,079 shares of the medical instruments supplier's stock valued at $9,980,000 after buying an additional 188,830 shares in the last quarter. Institutional investors own 96.70% of the company's stock.

STAAR Surgical Trading Down 0.1%

Shares of NASDAQ:STAA opened at $26.75 on Friday. The stock has a market capitalization of $1.32 billion, a P/E ratio of -13.86 and a beta of 0.74. The stock's 50-day moving average price is $25.32 and its 200-day moving average price is $20.23. STAAR Surgical Company has a 12-month low of $13.50 and a 12-month high of $38.60.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Canaccord Genuity Group upped their target price on shares of STAAR Surgical from $20.00 to $28.00 and gave the stock a "hold" rating in a research report on Wednesday, August 6th. Mizuho upped their price objective on STAAR Surgical from $17.00 to $18.00 and gave the stock a "neutral" rating in a report on Wednesday, July 16th. Piper Sandler upgraded STAAR Surgical to a "hold" rating in a research report on Wednesday, June 18th. Finally, Stifel Nicolaus set a $28.00 price objective on STAAR Surgical and gave the company a "hold" rating in a report on Thursday, August 7th. Ten analysts have rated the stock with a Hold rating, According to data from MarketBeat, STAAR Surgical currently has an average rating of "Hold" and a consensus target price of $20.67.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.